Expanded Access for Anti-IL8
NCT05210894 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2022-05-16
Summary
This is an expanded access designed to provide access to Anti-IL8 for eligible participants.
Interventions
- BIOLOGICAL
-
Anti-IL8
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Safety and Clinical Activity of Itolizumab in aGVHD
NCT05823675 ·Status: UNKNOWN ·Phase: PHASE1
-
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
NCT02810444 ·Status: COMPLETED ·Phase: PHASE3
-
B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency
NCT00024934 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Belimumab Administered Subcutaneously to Healthy Subjects
NCT01583530 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3549492 in Healthy Participants
NCT04758234 ·Status: COMPLETED ·Phase: PHASE1
-
Subcutaneous Pharmacokinetics of Belatacept
NCT00569803 ·Status: COMPLETED ·Phase: PHASE1
-
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
NCT04818346 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial
NCT05596786 ·Status: RECRUITING ·Phase: PHASE3
-
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
NCT05722912 ·Status: APPROVED_FOR_MARKETING
-
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
NCT00419341 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Access for BLZ-100 (Tozuleristide)
NCT04343274 ·Status: NO_LONGER_AVAILABLE
-
A Single-Dose Study of LY3471851 in Healthy Participants
NCT04998487 ·Status: COMPLETED ·Phase: PHASE1
-
Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)
NCT00719680 ·Status: COMPLETED ·Phase: PHASE3
-
Leniolisib for Immune Dysregulation in PIDs
NCT06549114 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants
NCT06243198 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
NCT04605926 ·Status: WITHDRAWN ·Phase: PHASE3
-
Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)
NCT00818168 ·Status: COMPLETED
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD
NCT00056264 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of MSB11455 in Healthy Participants
NCT03251339 ·Status: COMPLETED ·Phase: PHASE1
-
Hidradenitis Suppurativa Phase 2b Study of Izokibep
NCT05355805 ·Status: COMPLETED ·Phase: PHASE2
-
Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers
NCT03837093 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa
NCT00795574 ·Status: COMPLETED ·Phase: PHASE2